The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York 2023 FDA approvals: unprecedented volume at moderate value What is dihexa, its mechanism of action via the HGF c Met pathway, and its safety and clinical use? The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding spanning categories like